Literature DB >> 32096617

Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls

Philipp Ritter1, Falk Wieland1, Debra J. Skene1, Andrea Pfennig1, Maria Weiss1, Michael Bauer1, Emanuel Severus1, Henry Güldner1, Cathrin Sauer1, Bettina Soltmann1, Stefanie Neumann1.   

Abstract

Background: Multiple lines of evidence suggest that the onset and course of bipolar disorder is influenced by environmental light conditions. Increased suppression of melatonin by light (supersensitivity) in patients with bipolar disorder has been postulated as an endophenotype by several studies. However, due to methodological shortcomings, the results of these studies remain inconclusive. This study investigated melatonin suppression in euthymic patients with bipolar I disorder using evening blue light specifically targeting the melanopsin system.
Methods: Melatonin suppression was assessed in euthymic patients with bipolar I disorder and healthy controls by exposure to monochromatic blue light (λmax = 475 nm; photon density = 1.6 × 1013 photons/cm2/s) for 30 minutes at 2300 h, administered via a ganzfeld dome for highly uniform light exposure. Serum melatonin concentrations were determined from serial blood sampling via radioimmunoassay. All participants received mydriatic eye drops and were genotyped for the PER3 VNTR polymorphism to avoid or adjust for potential confounding. As secondary outcomes, serum melatonin concentrations during dark conditions and after monochromatic red light exposure (λmax = 624 nm; photon density = 1.6 × 1013 photons/cm2/s) were also investigated. Changes in subjective alertness were investigated for all 3 lighting conditions.
Results: A total of 90 participants (57 controls, 33 bipolar I disorder) completed the study. Melatonin suppression by monochromatic blue light did not differ between groups (F1,80 = 0.56; p = 0.46). Moreover, there were no differences in melatonin suppression by monochromatic red light (F1,82 = 1.80; p = 0.18) or differences in melatonin concentrations during dark conditions (F1,74 = 1.16; p = 0.29). Healthy controls displayed a stronger increase in subjective alertness during exposure to blue light than patients with bipolar I disorder (t85 = 2.28; p = 0.027). Limitations: Large interindividual differences in melatonin kinetics may have masked a true difference.
Conclusion: Despite using a large cohort and highly controlled laboratory conditions, we found no differences in melatonin suppression between euthymic patients with bipolar I disorder and healthy controls. These findings do not support the notion that supersensitivity is a valid endophenotype in bipolar I disorder.
© 2020 Joule Inc. or its licensors

Entities:  

Year:  2020        PMID: 32096617      PMCID: PMC7828907          DOI: 10.1503/jpn.190005

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  40 in total

Review 1.  New perspectives in melatonin uses.

Authors:  A Carpentieri; G Díaz de Barboza; V Areco; M Peralta López; N Tolosa de Talamoni
Journal:  Pharmacol Res       Date:  2012-01-30       Impact factor: 7.658

2.  Subjective and objective sleepiness in the active individual.

Authors:  T Akerstedt; M Gillberg
Journal:  Int J Neurosci       Date:  1990-05       Impact factor: 2.292

3.  Dark therapy for mania: a pilot study.

Authors:  Barbara Barbini; Francesco Benedetti; Cristina Colombo; Danilo Dotoli; Alessandro Bernasconi; Mara Cigala-Fulgosi; Marcello Florita; Enrico Smeraldi
Journal:  Bipolar Disord       Date:  2005-02       Impact factor: 6.744

4.  Human melatonin and alerting response to blue-enriched light depend on a polymorphism in the clock gene PER3.

Authors:  Sarah L Chellappa; Antoine U Viola; Christina Schmidt; Valérie Bachmann; Virginie Gabel; Micheline Maire; Carolin F Reichert; Amandine Valomon; Thomas Götz; Hans-Peter Landolt; Christian Cajochen
Journal:  J Clin Endocrinol Metab       Date:  2011-12-21       Impact factor: 5.958

5.  Pupillary and reaction time measures of sustained processing of negative information in depression.

Authors:  G J Siegle; E Granholm; R E Ingram; G E Matt
Journal:  Biol Psychiatry       Date:  2001-04-01       Impact factor: 13.382

Review 6.  Mood, the Circadian System, and Melanopsin Retinal Ganglion Cells.

Authors:  Lorenzo Lazzerini Ospri; Glen Prusky; Samer Hattar
Journal:  Annu Rev Neurosci       Date:  2017-05-17       Impact factor: 12.449

7.  Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers.

Authors:  Karen T Hallam; James S Olver; Jennifer E Horgan; Caroline McGrath; Trevor R Norman
Journal:  Int J Neuropsychopharmacol       Date:  2005-06       Impact factor: 5.176

8.  How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes.

Authors:  Paola Artioli; Cristina Lorenzi; Adele Pirovano; Alessandro Serretti; Francesco Benedetti; Marco Catalano; Enrico Smeraldi
Journal:  Eur Neuropsychopharmacol       Date:  2007-05-21       Impact factor: 4.600

9.  The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.

Authors:  D J Buysse; C F Reynolds; T H Monk; S R Berman; D J Kupfer
Journal:  Psychiatry Res       Date:  1989-05       Impact factor: 3.222

Review 10.  Signalling by melanopsin (OPN4) expressing photosensitive retinal ganglion cells.

Authors:  S Hughes; A Jagannath; J Rodgers; M W Hankins; S N Peirson; R G Foster
Journal:  Eye (Lond)       Date:  2016-01-15       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.